Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mayne Pharma Group Ltd.

www.maynepharma.com

Latest From Mayne Pharma Group Ltd.

Dr Reddy's Is Knocked Back On US NuvaRing And Copaxone Rivals

Dr Reddy’s has received a further CRL from the US Food and Drug Administration over its application for a generic rival to Merck Sharp & Dohme’s NuvaRing contraceptive, along with a CRL for its version of Teva’s Copaxone.

Regulation United States

Mayne Cannot Revive US Antifungals Patent

A late disclosure of interest for its parent group should not prevent Merck Sharp & Dohme from knocking down Mayne Pharma’s US antifungals formulation patent, the US Court of Appeals has ruled.

 

Intellectual Property United States

Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution

Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions... 

M & A Deals

Tech Transfer Roundup: Mustang Licenses St. Jude’s Gene Therapy For Bubble Boy Disease

Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.

Deals Intellectual Property
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Generic Drugs
    • OTC, Consumer
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • HalcyGen Pharmaceuticals Ltd.
  • FH Faulding & Co. Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Mayne Pharma Group Ltd.
  • Senior Management
  • Scott Richards, CEO, Managing Dir.
    Mark Cansdale, CFO
    Ilana Stancovski, PhD, CSO
    Peter Paltoglou, Chief Dev. Officer
  • Contact Info
  • Mayne Pharma Group Ltd.
    Phone: (61) 8 8209 2666
    1538 Main North Rd.
    Salisbury South, 5106
    Australia
Advertisement
Advertisement
UsernamePublicRestriction

Register